Delivery Order 75N98026D00014-75N98026F00002
Award Date 8/15/26
Potential Completion Date 8/14/32
Potential Value $2.5M
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost Plus Fixed Fee
Place of Performance
Kansas City, MO 64110, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
4
Legislative Mandate
Service Contract Act
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute on Drug Abuse issued a delivery order to Mriglobal (doing business as Midwest Research Institute) on July 20, 2026, with a ceiling value of $478,052, under a cost-plus-fixed-fee pricing structure for a Phase 1 single ascending dose pharmacokinetics study of parent and metabolite compounds as part of the Analytical Services Center for Medications Development. Place of performance is Kansas City, Missouri. The order extends through January 19, 2028. The delivery order...
- This is a $5,108,214.00 cost-plus-award-fee delivery order awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Mriglobal, doing business as Midwest Research Institute, a 501(c)(3) not-for-profit research organization. The contract is part of the Drug Manufacturing and Formulation Program (DMFP) with an ultimate completion date of September 18, 2029. Mriglobal has been awarded multiple significant federal contracts and grants, including Indefinite Delivery Contracts...
- This is a delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency of the U.S. Department of Health and Human Services, to Mriglobal (doing business as Midwest Research Institute), a 501(c)(3) not-for-profit research organization. The contract is part of NIDA's Drug Manufacturing and Formulation Program (DMFP) and is for small-scale testing of convergent route processes. The contract has a ceiling value of $942,363.89 and does not have a set-aside...
- This is a Cost Plus Award Fee delivery order under a $1,283,149.00 contract awarded by the National Institute of Neurological Disorders and Stroke, a civilian agency, to Mriglobal (also known as Midwest Research Institute), a 501(c)(3) not-for-profit research organization. The contract is part of the Drug Manufacturing and Formulation Program (DMFP) master IDIQ, and the task is for the PADERI HEAL PROJECT-IHP-102. There is no set-aside designation for this award. Mriglobal is the prime...
- The National Institute on Drug Abuse issued a delivery order to Mriglobal (doing business as Midwest Research Institute) on July 20, 2026, with a ceiling value of $382,839, under a cost-plus-fixed-fee pricing structure for Phase 1 single ascending dose pharmacokinetics study analytical services. The order runs through January 19, 2028. Place of performance is Kansas City, Missouri. This task order (DAP-NCAP-00000009) supports the Analytical Services Center for Medications Development, part of...
- The National Cancer Institute awarded a delivery order valued at $2.79 million to Mriglobal (doing business as Midwest Research Institute) on September 25, 2024, for the manufacture of plasmid DNA drug substance and drug product. This contract, which is not subject to any small business set-aside designation, is structured as a cost-plus-no-fee arrangement with a completion date of April 30, 2028, and will be performed in Rockville, Maryland. Plasmid DNA represents an important class of...
- The National Institute on Drug Abuse issued a $131,900 delivery order to Mriglobal (doing business as Midwest Research Institute) on June 3, 2022, under the CRO Support for NCATS Drug Substance Development and Manufacture contract for stability studies on ML-246 (METARRESTIN) and contract research organization support for drug substance development and manufacture. Place of performance is Kansas City, MO. The order is firm fixed price with an ultimate completion date of January 30, 2028. No...
- This is a delivery order award under the Drug Manufacturing and Formulation Program (DMFP) Indefinite Delivery/Indefinite Quantity (IDIQ) contract, which was awarded to Curia Global Inc. (doing business as Amri), a for-profit organization and manufacturer of goods. The award, valued at $3,140,340.00, is for the National Institute of Neurological Disorders and Stroke (NINDS), a civilian federal agency. The contract is a Cost Plus Fixed Fee type, with an ultimate completion date of September 16,...
- The National Institute on Drug Abuse (NIDA), on behalf of the National Institute of Neurological Disorders and Stroke (NINDS), issued a purchase order to Curia Global Inc. (doing business as Amri) on September 19, 2024, for non-GMP synthesis of compounds, with a ceiling value of $1,785,511.20. The order supports a medicinal chemistry discovery program focused on identifying molecules that bind the KIAA0203 protein for potential Alzheimer's drug development. Work is performed in Buffalo, New...
- This is a cost-plus-fixed-fee delivery order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Mriglobal, doing business as Midwest Research Institute, a non-profit research organization. The contract is valued at $949,295.00 and will run through January 31, 2026. The contract is for the evaluation of the shelf-life of samples of investigational clinical drug formulations, including parenteral, oral, and other dosage...